GSK 239512

Drug Profile

GSK 239512

Alternative Names: 239512; GSK239512

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antidementias; Antipsychotics
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • No development reported Alzheimer's disease
  • Discontinued Schizophrenia

Most Recent Events

  • 29 Jun 2015 Discontinued - Phase-II for Schizophrenia in USA (PO)
  • 29 Jun 2015 No recent reports on development identified - Phase-I for Alzheimer's disease in Australia (PO)
  • 29 Jun 2015 No recent reports on development identified - Phase-II for Alzheimer's disease in Russia, South Korea, Chile, European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top